Literature DB >> 29625133

Commentary: Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality?: A critical question that we are only just beginning to answer.

Joel M Gelfand1.   

Abstract

Entities:  

Keywords:  TNF inhibitor; biologic; cardiovascular; mortality; myocardial infarction; psoriasis; stroke

Mesh：

Substances：

Year:  2018        PMID： 29625133      PMCID： PMC6004329          DOI： 10.1016/j.jaad.2018.03.046

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  7 in total

1.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

2.  Objective Measures of Psoriasis Severity Predict Mortality: A Prospective Population-Based Cohort Study.

Authors:  Megan H Noe; Daniel B Shin; Marilyn T Wan; Joel M Gelfand
Journal:  J Invest Dermatol       Date:  2017-08-23       Impact factor: 8.551

3.  TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study.

Authors:  Robert Bissonnette; François Harel; James G Krueger; Marie-Claude Guertin; Malorie Chabot-Blanchet; Juana Gonzalez; Catherine Maari; Isabelle Delorme; Charles W Lynde; Jean-Claude Tardif
Journal:  J Invest Dermatol       Date:  2017-03-09       Impact factor: 8.551

4.  The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study.

Authors:  Jashin J Wu; Murali Sundaram; Martin Cloutier; Marjolaine Gauthier-Loiselle; Annie Guérin; Rakesh Singh; Arijit Ganguli
Journal:  J Am Acad Dermatol       Date:  2018-03-01       Impact factor: 11.527

5.  The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: an Updated Meta-Analysis.

Authors:  Zheng-Sheng Yang; Ning-Ning Lin; Li Li; Yang Li
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

6.  Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.

Authors:  K Abuabara; R S Azfar; D B Shin; A L Neimann; A B Troxel; J M Gelfand
Journal:  Br J Dermatol       Date:  2010-09       Impact factor: 9.302

7.  Research Techniques Made Simple: Pharmacoepidemiology Research Methods in Dermatology.

Authors:  Megan H Noe; Joel M Gelfand
Journal:  J Invest Dermatol       Date:  2018-02       Impact factor: 8.551
  7 in total
  8 in total

1.  Updates in Psoriasis Management: Based on selected presentations from Maui Derm 2020, January 25-29, 2020, Maui, Hawaii.

Authors:  Jo Ann Lequang
Journal:  J Clin Aesthet Dermatol       Date:  2020-07-01

2.  Detailed Long-term Dynamics of Neutrophil-to-Lymphocyte Ratio under Biologic Treatment Reveals Differential Effects of Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists.

Authors:  Jochen H O Hoffmann; Christian Knoop; Alexander Enk; Eva N Hadaschik
Journal:  Acta Derm Venereol       Date:  2021-09-30       Impact factor: 3.875

3.  A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S).

Authors:  Joel M Gelfand; Daniel B Shin; Kristina Callis Duffin; April W Armstrong; Andrew Blauvelt; Stephen K Tyring; Alan Menter; Scott Gottlieb; Benjamin N Lockshin; Eric L Simpson; Farid Kianifard; Rajendra Prasad Sarkar; Elisa Muscianisi; Jennifer Steadman; Mark A Ahlman; Martin P Playford; Aditya A Joshi; Amit K Dey; Thomas J Werner; Abass Alavi; Nehal N Mehta
Journal:  J Invest Dermatol       Date:  2020-02-21       Impact factor: 8.551

4.  Evaluation of Psoriasis Area and Severity Index as a Proxy for Bio-markers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment Cycles.

Authors:  Jochen H O Hoffmann; Christian Knoop; Knut Schäkel; Alexander H Enk; Eva N Hadaschik
Journal:  Acta Derm Venereol       Date:  2021-05-25       Impact factor: 3.875

Review 5.  Secukinumab in the treatment of psoriasis: patient selection and perspectives.

Authors:  Eric J Yang; Kristen M Beck; Wilson Liao
Journal:  Psoriasis (Auckl)       Date:  2018-10-17

6.  Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.

Authors:  Subrata Ghosh; Lianne S Gensler; Zijiang Yang; Chris Gasink; Soumya D Chakravarty; Kamyar Farahi; Paraneedharan Ramachandran; Elyssa Ott; Bruce E Strober
Journal:  Drug Saf       Date:  2019-06       Impact factor: 5.606

Review 7.  Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis.

Authors:  Jeremy G Light; Jennifer J Su; Steven R Feldman
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-01-15

8.  A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology.

Authors:  Tadas Raudonis; Akvile Gliebute; Anna Greta Grigaityte; Zivile Lukosiunaite; Tatjana Karmaziene; Jurate Grigaitiene
Journal:  Medicina (Kaunas)       Date:  2020-06-04       Impact factor: 2.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.